Key result
Histologic response to neoadjuvant chemotherapy (19% excellent, 10% moderate, 71% poor) did not correlate with overall or event-free survival in patients with extremity soft tissue sarcoma.
Why the study?
Does histologic response to neoadjuvant chemotherapy predict overall or event-free survival in patients with high-grade extremity soft tissue sarcoma?
Population
31 patients with tumor stage T2 grade 3 extremity soft tissue sarcomas
Design
Cohort
Authors
Loading...
Histologic response should not guide prognosis or neoadjuvant decisions in extremity STS; challenges its validity as a surrogate endpoint.
Cohort (n=31)
No
Does histologic response to neoadjuvant chemotherapy predict overall or event-free survival in patients with high-grade extremity soft tissue sarcoma?
Histologic response to neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma does not reliably predict overall or event-free survival.
Lucas et al. (2008) conducted a cohort in Tumor stage T2 grade 3 extremity soft tissue sarcomas (n=31). Histologic response to neoadjuvant chemotherapy was evaluated on Overall or event-free survival. Histologic response to neoadjuvant chemotherapy (19% excellent, 10% moderate, 71% poor) did not correlate with overall or event-free survival in patients with extremity soft tissue sarcoma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: